Undisclosed pan-RAS inhibitor / Qualigen Therap - LARVOL DELTA

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire) - "Results demonstrated the compounds' role as Pan-RAS inhibitors. These compounds effectively target and disrupt the activity and signaling of various RAS mutations, including K-RAS, H-RAS, and N-RAS, impacting both mutant and wild type variants. Encouragingly, in vivo studies indicate minimal toxicity associated with these compounds, likely due to their selective suppression of RAS signaling at the administered doses."

Preclinical • Oncology • Solid Tumor